Overview

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD

Status:
RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Phase:
PHASE3
Details
Lead Sponsor:
Ironshore Pharmaceuticals and Development, Inc
Collaborator:
Collegium Pharmaceutical, Inc.
Treatments:
Methylphenidate